KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: Özel Sayı 1

One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARSCoV-2 vaccines for holistic management and achieving global control

Eskild PETERSEN
Asma Al BALUSHI
Alimuddin ZUMLA
Deniz GÖKENGİN
Sayfa
3157–3161
Yayın Tarihi
2022-11-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Preventing long term sequelae of COVID-19 also remains a priority.Key words: COVID-19, Vaccines, surveillance, zoonosis, variants

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Abstract: One and a half years into the pandemic, SARS-CoV-2 is still here to stay.
📊
Temel Bulgular & Veri:Whilst rapid several effective COVID-19 vaccines have been developed and are being rolled out, the critical questions remain whether vaccines provide widespread protection against infection and reinfection, and what the duration of protection is.
💡
Sonuç & Katkı:Preventing long term sequelae of COVID-19 also remains a priority.Key words: COVID-19, Vaccines, surveillance, zoonosis, variants
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Abstract: One and a half years into the pandemic, SARS-CoV-2 is still here to stay. Whilst rapid several effective COVID-19 vaccines have been developed and are being rolled out, the critical questions remain whether vaccines provide widespread protection against infection and reinfection, and what the duration of protection is. Community wide control cannot be obtained until almost everyone is immune. Vaccine production must be ramped up to cover the world population. The price of herd immunity through natural infection is high mortality in the elderly and morbidity in other age groups including children and Long-COVID. We must expect a new wave in the coming winter. The severity will depend on the proportion of the population with immunity from natural infections or immunisation. Therefore, control rests on a population wide immunisation including children, which may or may not need to be repeated if new SARSCoV-2 variants evolve that can escape immunity from either previous infections or immunisations. Preventing long term sequelae of COVID-19 also remains a priority.Key words: COVID-19, Vaccines, surveillance, zoonosis, variants

🔖

Bu Makaleye Atıf Yap

PETERSEN, E., BALUSHI, A. A., ZUMLA, A., GÖKENGİN, D. (2022). One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARSCoV-2 vaccines for holistic management and achieving global control. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: Özel Sayı 1, 3157–3161. https://ajindex.com/articles/609476

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Fontanet A Cauchemez S. COVID-19 herd immunity: where are we? Nature Reviews of Immunology 2020
  2. doi: 10.1038/s41577-020-00451-5 2. Sanyang B, Kanteh A, Usuf E, Nadjm B, Jarju S et al. COVID-19 reinfections in The Gambia by phylogenetically distinct SARSCoV-2 variants—first two confirmed events in west Africa. The Lancet Global Health 3 June 2021. doi:https://doi.org/10.1016/ S2214-109X(21)00213-8 3. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A et al. The implications of silent transmission for the control of COVID-19 outbreak. Proceedings of the National Academy of Science USA. 2020
  3. 17513–17515. doi: 10.1073/ pnas.2008373117 4. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infectious Diseases 2020
  4. 20(9): e238-e244. doi: 10.1016/S1473-3099(20)30484-9 5. Petersen E, Buchy P. Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. International Journal of Infectious Diseases 2021
  5. doi: 10.1016/j. ijid.2021.04.082 6. Piroth L, Cottenet J, Mariet A-S, Bonniaud P, Blot M et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, populationbased retrospective cohort study. Lancet Respiratory Medicine 2020
  6. 9(3): 251-259. doi: 10.1016/S2213-2600(20)30527-0 7. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines. Science Immunology 2021
  7. 6(59): eabj1750. doi:10.1126/sciimmunol.abj1750 8. Milman O, Yelin I, Aharony N, Katz R, Herzel E et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nature Medicine 2021 10th June. doi: 10.1038/s41591-021-01407-5 9. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020
  8. 368(6493): 860-868. doi: 10.1126/science.abb5793 10. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 2021: 371 (6530): 741-745. doi.10.1126/ science.abe6522 11. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine 2021 July 9th. doi: 10.1038/ s41591-021-0144